Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Accumulated Expenses (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Accumulated Expenses for 11 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 74.95% to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Dec 2025, down 74.95% year-over-year, with the annual reading at $2.7 million for FY2025, 74.95% down from the prior year.
  • Accumulated Expenses hit $2.7 million in Q4 2025 for Seres Therapeutics, down from $4.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $59.8 million in Q4 2022 to a low of $2.7 million in Q4 2025.
  • Historically, Accumulated Expenses has averaged $19.8 million across 5 years, with a median of $11.2 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 1147.13% in 2021 and later plummeted 86.17% in 2024.
  • Year by year, Accumulated Expenses stood at $45.1 million in 2021, then skyrocketed by 32.7% to $59.8 million in 2022, then tumbled by 62.38% to $22.5 million in 2023, then tumbled by 52.38% to $10.7 million in 2024, then tumbled by 74.95% to $2.7 million in 2025.
  • Business Quant data shows Accumulated Expenses for MCRB at $2.7 million in Q4 2025, $4.4 million in Q3 2025, and $4.2 million in Q2 2025.